Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI-120 vs Neulasta Immunogenicity Study in Healthy Adults
NCT03202927Phase 1Completed
- Sponsor
- Adello Biologics, LLC
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of pegfilgrastim-apgf in febrile neutropenia (FN) and neutropenia (2 arms), sponsored by Adello Biologics, LLC. Primary endpoint: Treatment emergent ADA incidence rate at Day 58. Started Mar 2017; status: completed.
02
Drugs
pegfilgrastim-apgf
03
Conditions
febrile neutropenia (FN)neutropenia
Beyond the preview
Go deeper on NCT03202927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202927.